S*BIO Raises $26 Million
S*BIO Pte Ltd., a Singapore-based cancer therapeutics company, has raised $26 million in Series B funding. Aravis Capital and return backer Bio*One Capital co-led the round, and were joined by existing investors like Zurcher Kantonalbank and the Lacuna Apo BioTech Fund. The company has two lead compounds in Phase 1 clinical trials: One is an HDAC inhibitor, while the other is a JAK 2 inhibitor.
20 October 2008•5 mins read
